SCHEMBL6740754

SCHEMBL6740754

Nc1ccc(B(O)O)c(C(=O)C(F)(F)F)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.38
MEN1 O00255 3/20 0.38
THRB P10828 3/20 0.38
KMT2A Q03164 3/20 0.38
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 3/20 0.38
RECQL P46063 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
POLB P06746 2/20 0.38
ALOX15 P16050 2/20 0.38
HSD17B10 Q99714 2/20 0.38
CYP3A4 P08684 2/20 0.38
USP2 O75604 1/20 0.38
PKM P14618 1/20 0.38
APEX1 P27695 1/20 0.38
BLM P54132 1/20 0.38
MCL1 Q07820 1/20 0.38
TNF P01375 1/20 0.38
HSPD1 P10809 1/20 0.38
CYP2C9 P11712 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3786793 0.81 ACHE (0.45) ACHECES1PLA2G2D
SCHEMBL3793008 0.78 KDM4E (0.57) MAPTMEN1THRBKMT2AKDM4E
SCHEMBL24166639 0.77 MAPT (0.41) MAPTMEN1THRBKMT2AKDM4E
SCHEMBL1275130 0.76 CES1 (0.48) KDM4EHTTACHEIDO1CES1
SCHEMBL31555481 0.74 GAA (0.59) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL28352560 0.73 NR1H2 (0.42) MAPTMEN1THRBKMT2AKDM4E
SCHEMBL29952929 0.72 ACHE (0.44) MAPTTDP1ACHECES1
SCHEMBL3785393 0.71 ACHE (0.46) ACHECES1PLA2G2D
SCHEMBL3785258 0.71 TSHR (0.55) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL28458790 0.67 ALDH1A1 (0.40) MAPTMEN1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6689770-B2 AN INHIBITORS OF TRYPSIN-LIKE SERINE PROTEASE ENZYMES, AS ANTICOAGULANT AGENTS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISORDERS BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-02-10 US disclosed
EP-1175419-B1 ARYL SULFONYLS AS FACTOR XA INHIBITORS BRISTOL MYERS SQUIBB PHARMA CO (US) 2003-05-28 EP disclosed
US-20030050315-A1 Aryl sulfonyls as factor Xa inhibitors WEXLER RUTH R (US) 2003-03-13 US disclosed
US-6399644-B1 ANTICOAGULANTS DUPONT PHARMACEUTICALS COMPANY 2002-06-04 US disclosed
EP-1175419-A2 ARYL SULFONYLS AS FACTOR XA INHIBITORS Du Pont Pharmaceuticals Company (US) 2002-01-30 EP disclosed
WO-2000059902-A2 ARYL SULFONYLS AS FACTOR XA INHIBITORS DU PONT PHARMACEUTICALS COMPANY (US) 2000-10-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030050315-A1 Aryl sulfonyls as factor Xa inhibitors F12, F11, TFPI MAPT 4838/4885MEN1 1216/4885THRB 2118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.